Description de l'entreprise
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
Conseil d'administration & Conseil de surveillance
PDG |
Ugur Sahin |
Conseil d'administration |
Jens Holstein, Özlem Türeci, Ryan Richardson, Sean Marett, Sierk Poetting |
Conseil de surveillance |
Helmut Jeggle, Michael Motschmann, Prof. Christoph Huber, Ulrich Wandschneider |
Données de l'entreprise
Nom: |
BioNTech SE |
Adresse: |
An der Goldgrube 12,DE-55131 Mainz |
Téléphone: |
+49-6131-9084-0 |
Fax: |
+49-6131-9084-390 |
Courriel: |
info@biontech.de
|
Internet: |
https://biontech.de/de |
Industrie: |
Biotechnology |
Secteur: |
Biotechnology |
Sous-secteur: |
Biotechnology |
Fin de l'exercice financier: |
31/12 |
Flotte libre: |
- |
IPO date: |
- |
Relations avec les investisseurs
Nom: |
Dr. Sylke Maas |
Téléphone IR: |
- |
IR-Fax: |
- |
E-mail IR: |
Investors@biontech.de
|